Cholesterol management guidelines emphasize earlier prevention

The AHA and ACC published updated dyslipidemia guidelines that emphasize earlier, lifestyle-based prevention and introduce a contemporary risk tool (PREVENT) plus additional tests to refine heart attack and stroke risk assessment. The updates also address treatments for high triglycerides and recommend universal cholesterol screening for children ages 9 to 11.

The American Heart Association and American College of Cardiology published updated dyslipidemia guidelines in the journal Circulation. The revisions emphasize earlier intervention through healthy lifestyle measures and offer updated approaches for estimating cardiovascular risk. The guidance introduces the PREVENT risk calculator and recommends additional testing in some cases to better identify risk. The document also discusses treatment options for high triglycerides and recommends cholesterol screening for children ages 9 to 11. Key points: - The AHA and ACC released updated guidelines for managing dyslipidemia, published in Circulation. - The guidelines emphasize earlier, lifestyle-based prevention across the lifespan rather than waiting until disease appears. - They recommend using the PREVENT risk calculator, which provides 10-year and 30-year estimates and can inform risk discussions for people as young as 30. - Additional tests named in the guidance include coronary artery calcium (CAC) scans and blood markers such as lipoprotein(a) and apolipoprotein B to refine risk assessment. - The guidance addresses hypertriglyceridemia, noting that very high triglycerides (over 500 mg/dL) can raise pancreatitis risk and that newer therapies like olezarsen and plozasiran are discussed. - The guidelines recommend universal cholesterol screening for children aged 9 to 11 to help identify familial and lifestyle-related lipid disorders early. Summary: The updates aim to support earlier, individualized conversations about cardiovascular risk and broaden the tools clinicians may use to assess and manage dyslipidemia. How widely clinical practice will change in coming months is undetermined at this time.